Cargando…
Assessment of automated high-throughput serological assays for prediction of high-titer SARS-CoV-2 neutralizing antibody
COVID19 convalescent patient plasma units with high titer neutralizing antibody can be used to treat patients with severe disease. Therefore, in order to select suitable donors, neutralizing antibody titer against SARS CoV-2 needs to be determined. Because the neutralization assay is highly demandin...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Author(s). Published by Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8093006/ https://www.ncbi.nlm.nih.gov/pubmed/35262004 http://dx.doi.org/10.1016/j.jcvp.2021.100016 |
_version_ | 1783687724193021952 |
---|---|
author | Moscato, Giovanna Mazzetti, Paola Lucenteforte, Ersilia Rosellini, Alfredo Cara, Alice Quaranta, Paola Mainardi, Valerio Villa, Pietro Focosi, Daniele Lanza, Maria Bianco, Irene Mazzoni, Alessandro Falcone, Marco Menichetti, Francesco Maggi, Fabrizio Lai, Michele Freer, Giulia Pistello, Mauro |
author_facet | Moscato, Giovanna Mazzetti, Paola Lucenteforte, Ersilia Rosellini, Alfredo Cara, Alice Quaranta, Paola Mainardi, Valerio Villa, Pietro Focosi, Daniele Lanza, Maria Bianco, Irene Mazzoni, Alessandro Falcone, Marco Menichetti, Francesco Maggi, Fabrizio Lai, Michele Freer, Giulia Pistello, Mauro |
author_sort | Moscato, Giovanna |
collection | PubMed |
description | COVID19 convalescent patient plasma units with high titer neutralizing antibody can be used to treat patients with severe disease. Therefore, in order to select suitable donors, neutralizing antibody titer against SARS CoV-2 needs to be determined. Because the neutralization assay is highly demanding from several points of view, a pre-selection of sera would be desirable to minimize the number of sera to be tested. In this study, a total of 140 serum samples that had been titrated for SARS-CoV-2 neutralizing antibody by microneutralization assay were also tested for the presence of anti-SARS-CoV2 antibody using 5 different tests: Architect® immunoassay (Abbott Diagnostics), detecting IgG against the nucleocapsid protein, LIAISON XL® (Diasorin) detecting IgG against a recombinant form of the S1/S2 subunits of the spike protein, VITROS® (Ortho Clinical Diagnostics), detecting IgG against a recombinant form of the spike protein, and ELISA (Euroimmun AG), detecting IgA or IgG against a recombinant form of the S1 subunit. To determine which immunoassay had the highest chance to detect sera with neutralizing antibodies above a certain threshold, we compared the results obtained from the five immunoassays with the titers obtained by microneutralization assay by linear regression analysis and by using receiver operating characteristic curve and Youden's index. Our results indicate that the most suitable method to predict sera with high Nab titer is Euroimmun® IgG, followed closely by Ortho VITROS® Anti-SARS-CoV-2 IgG. |
format | Online Article Text |
id | pubmed-8093006 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | The Author(s). Published by Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-80930062021-05-05 Assessment of automated high-throughput serological assays for prediction of high-titer SARS-CoV-2 neutralizing antibody Moscato, Giovanna Mazzetti, Paola Lucenteforte, Ersilia Rosellini, Alfredo Cara, Alice Quaranta, Paola Mainardi, Valerio Villa, Pietro Focosi, Daniele Lanza, Maria Bianco, Irene Mazzoni, Alessandro Falcone, Marco Menichetti, Francesco Maggi, Fabrizio Lai, Michele Freer, Giulia Pistello, Mauro Journal of Clinical Virology Plus Article COVID19 convalescent patient plasma units with high titer neutralizing antibody can be used to treat patients with severe disease. Therefore, in order to select suitable donors, neutralizing antibody titer against SARS CoV-2 needs to be determined. Because the neutralization assay is highly demanding from several points of view, a pre-selection of sera would be desirable to minimize the number of sera to be tested. In this study, a total of 140 serum samples that had been titrated for SARS-CoV-2 neutralizing antibody by microneutralization assay were also tested for the presence of anti-SARS-CoV2 antibody using 5 different tests: Architect® immunoassay (Abbott Diagnostics), detecting IgG against the nucleocapsid protein, LIAISON XL® (Diasorin) detecting IgG against a recombinant form of the S1/S2 subunits of the spike protein, VITROS® (Ortho Clinical Diagnostics), detecting IgG against a recombinant form of the spike protein, and ELISA (Euroimmun AG), detecting IgA or IgG against a recombinant form of the S1 subunit. To determine which immunoassay had the highest chance to detect sera with neutralizing antibodies above a certain threshold, we compared the results obtained from the five immunoassays with the titers obtained by microneutralization assay by linear regression analysis and by using receiver operating characteristic curve and Youden's index. Our results indicate that the most suitable method to predict sera with high Nab titer is Euroimmun® IgG, followed closely by Ortho VITROS® Anti-SARS-CoV-2 IgG. The Author(s). Published by Elsevier Ltd. 2021-06 2021-05-04 /pmc/articles/PMC8093006/ /pubmed/35262004 http://dx.doi.org/10.1016/j.jcvp.2021.100016 Text en © 2021 The Author(s) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Moscato, Giovanna Mazzetti, Paola Lucenteforte, Ersilia Rosellini, Alfredo Cara, Alice Quaranta, Paola Mainardi, Valerio Villa, Pietro Focosi, Daniele Lanza, Maria Bianco, Irene Mazzoni, Alessandro Falcone, Marco Menichetti, Francesco Maggi, Fabrizio Lai, Michele Freer, Giulia Pistello, Mauro Assessment of automated high-throughput serological assays for prediction of high-titer SARS-CoV-2 neutralizing antibody |
title | Assessment of automated high-throughput serological assays for prediction of high-titer SARS-CoV-2 neutralizing antibody |
title_full | Assessment of automated high-throughput serological assays for prediction of high-titer SARS-CoV-2 neutralizing antibody |
title_fullStr | Assessment of automated high-throughput serological assays for prediction of high-titer SARS-CoV-2 neutralizing antibody |
title_full_unstemmed | Assessment of automated high-throughput serological assays for prediction of high-titer SARS-CoV-2 neutralizing antibody |
title_short | Assessment of automated high-throughput serological assays for prediction of high-titer SARS-CoV-2 neutralizing antibody |
title_sort | assessment of automated high-throughput serological assays for prediction of high-titer sars-cov-2 neutralizing antibody |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8093006/ https://www.ncbi.nlm.nih.gov/pubmed/35262004 http://dx.doi.org/10.1016/j.jcvp.2021.100016 |
work_keys_str_mv | AT moscatogiovanna assessmentofautomatedhighthroughputserologicalassaysforpredictionofhightitersarscov2neutralizingantibody AT mazzettipaola assessmentofautomatedhighthroughputserologicalassaysforpredictionofhightitersarscov2neutralizingantibody AT lucenteforteersilia assessmentofautomatedhighthroughputserologicalassaysforpredictionofhightitersarscov2neutralizingantibody AT rosellinialfredo assessmentofautomatedhighthroughputserologicalassaysforpredictionofhightitersarscov2neutralizingantibody AT caraalice assessmentofautomatedhighthroughputserologicalassaysforpredictionofhightitersarscov2neutralizingantibody AT quarantapaola assessmentofautomatedhighthroughputserologicalassaysforpredictionofhightitersarscov2neutralizingantibody AT mainardivalerio assessmentofautomatedhighthroughputserologicalassaysforpredictionofhightitersarscov2neutralizingantibody AT villapietro assessmentofautomatedhighthroughputserologicalassaysforpredictionofhightitersarscov2neutralizingantibody AT focosidaniele assessmentofautomatedhighthroughputserologicalassaysforpredictionofhightitersarscov2neutralizingantibody AT lanzamaria assessmentofautomatedhighthroughputserologicalassaysforpredictionofhightitersarscov2neutralizingantibody AT biancoirene assessmentofautomatedhighthroughputserologicalassaysforpredictionofhightitersarscov2neutralizingantibody AT mazzonialessandro assessmentofautomatedhighthroughputserologicalassaysforpredictionofhightitersarscov2neutralizingantibody AT falconemarco assessmentofautomatedhighthroughputserologicalassaysforpredictionofhightitersarscov2neutralizingantibody AT menichettifrancesco assessmentofautomatedhighthroughputserologicalassaysforpredictionofhightitersarscov2neutralizingantibody AT maggifabrizio assessmentofautomatedhighthroughputserologicalassaysforpredictionofhightitersarscov2neutralizingantibody AT laimichele assessmentofautomatedhighthroughputserologicalassaysforpredictionofhightitersarscov2neutralizingantibody AT freergiulia assessmentofautomatedhighthroughputserologicalassaysforpredictionofhightitersarscov2neutralizingantibody AT pistellomauro assessmentofautomatedhighthroughputserologicalassaysforpredictionofhightitersarscov2neutralizingantibody |